Početna stranicaNVON • BMV
add
Novo Nordisk A/S
Preth. zaklj. cijena
683,81 $
Dnevni raspon
676,00 $ - 692,00 $
Godišnji raspon
638,00 $ - 1.624,38 $
Tržišna kapitalizacija
128,86 mlr. USD
Prosječna količina
10,33 tis.
P/E omjer
-
Prinos dividende
-
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (DKK) | pro 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 79,14 mlr. | −7,63 % |
Operativni troškovi | 29,73 mlr. | 12,96 % |
Neto dohodak | 26,89 mlr. | −4,74 % |
Neto profitabilnost | 33,98 | 3,13 % |
Zarada po dionici | 6,04 | −4,73 % |
EBITDA | 36,66 mlr. | −23,44 % |
Efektivna porezna stopa | 21,34 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (DKK) | pro 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 26,96 mlr. | 2,49 % |
Ukupna imovina | 542,90 mlr. | 16,60 % |
Ukupne obveze | 348,86 mlr. | 8,29 % |
Ukupni kapital | 194,05 mlr. | — |
Dionice u optjecaju | 4,44 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 15,66 | — |
Povrat imovine | 16,70 % | — |
Povrat kapitala | 29,56 % | — |
Tok novca
Neto promjena novca
| (DKK) | pro 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 26,89 mlr. | −4,74 % |
Gotovina od poslovanja | 7,62 mlr. | −38,06 % |
Gotovina iz ulaganja | −42,81 mlr. | 53,07 % |
Gotovina iz financiranja | 29,47 mlr. | −20,00 % |
Neto promjena novca | −5,62 mlr. | 86,41 % |
Slobodan tok novca | −34,95 mlr. | −1.011,09 % |
Više
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Glavni izvršni direktor
Osnovano
21. pro 1923.
Sjedište
Web-lokacija
Zaposlenici
69.150